According to the FDA, GlaxoSmithKline has reported that 20 mg and 5 mg dosages of its Imitrex nasal spray for the treatment of migraine headaches will be unavailable until February 2016 due to an API shortage. The shortage, which was reported to the FDA on November 20, 2015, affects both dosages of an authorized generic sumatriptan nasal spray distributed by Sandoz as well.
Imitrex and generic sumatriptan are also available in tablet form and as an injection, neither of which is currently listed as in shortage on the FDA website.
View the FDA drug shortage report.
